BioLineRx Raises USD 10m in offering
Categories: Capital Markets
BioLineRx Ltd., a clinical-stage biopharmaceutical company specialising in oncology, has completed a USD 10 million registered direct offering. The Israel-based firm is dedicated to developing innovative treatments to improve outcomes for cancer patients.
The offering underscores investor confidence in BioLineRx’s groundbreaking pipeline of oncology therapies. The proceeds will support ongoing clinical development and advance its mission to deliver transformative solutions in cancer care.
Greenberg Traurig’s Tel Aviv team, led by Capital Markets shareholder Gary Emmanuel, with support from attorneyMichael Soumas, represented BioLineRx in this pivotal transaction.